NATCO Pharma Limited (BOM:524816)
797.75
+4.75 (0.60%)
At close: Feb 21, 2025
NATCO Pharma Revenue
NATCO Pharma had revenue of 4.75B INR in the quarter ending December 31, 2024, a decrease of -37.41%. This brings the company's revenue in the last twelve months to 42.80B, up 11.76% year-over-year. In the fiscal year ending March 31, 2024, NATCO Pharma had annual revenue of 40.02B with 47.76% growth.
Revenue (ttm)
42.80B
Revenue Growth
+11.76%
P/S Ratio
n/a
Revenue / Employee
10.66M
Employees
4,016
Market Cap
142.92B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 40.02B | 12.94B | 47.76% |
Mar 31, 2023 | 27.09B | 7.62B | 39.17% |
Mar 31, 2022 | 19.46B | -1.10B | -5.35% |
Mar 31, 2021 | 20.56B | 1.41B | 7.37% |
Mar 31, 2020 | 19.15B | -1.80B | -8.57% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,398.38B |
Tata Consultancy Services | 2,520.82B |
HDFC Bank | 2,702.59B |
Bharti Airtel | 1,627.08B |
ICICI Bank | 1,755.26B |
Infosys | 1,635.60B |
State Bank of India | 3,409.52B |
Hindustan Unilever | 626.61B |
NATCO Pharma News
- 3 days ago - Stocks hitting 52-week low today, February 20: Natco Pharma, VIP Industries, Birlasoft and more - Business Upturn
- 4 days ago - Stocks hitting 52-week low today, February 19: Natco Pharma, Godrej Consumer, Trident, BEML and more - Business Upturn
- 9 days ago - Natco Pharma Ltd (BOM:524816) Q3 2025 Earnings Call Highlights: Navigating Challenges with ... - GuruFocus
- 9 days ago - Natco Pharma shares drop 30% in 2 days following poor Q3 results - Business Upturn
- 10 days ago - Top market losers: Natco Pharma plunges 18.65%, Vijaya Diagnostic down 7.20%, Godfrey Phillips slips 4.18% - Business Upturn
- 10 days ago - Natco Pharma shares drop 16% as Q3 revenue falls 37% YoY - Business Upturn
- 11 days ago - Natco Pharma Q3 FY25 Results: Revenue down 37.4% to Rs 475 crore, Net Profit declines 37.8% YoY - Business Upturn
- 13 days ago - Lupin and Natco Pharma gets USFDA nod for Generic Bosentan tablets - Business Upturn